Key indicators: single-crystal X-ray study; T = 98 K; mean (C-C) = 0.003 Å; R factor = 0.056; wR factor = 0.128; data-to-parameter ratio = 12.0.
In the title co-crystal, C 10 H 8 N 2 Á2C 5 H 7 NO 3 , the 4,4 0 -bipyridine molecule [dihedral angle between the pyridine rings = 36.33 (11) ] accepts O-HÁ Á ÁN hydrogen bonds from the two pyroglutamic (pga) acid molecules. The pga molecules at each end of the trimeric aggregate self-associate via centrosymmetric eight-membered amide {Á Á ÁHNCO} 2 synthons, so that the crystal structure comprises one-dimensional supramolecular chains propagating in [132] . C-HÁ Á ÁO andstacking interactions [centroid-centroid separation = 3.590 (2) Å ] consolidate the structure.
Related literature
For background to the co-crystallization of active pharmaceutical agents and discussion on the definition of a co-crystal, see: Shan & Zaworotko (2008) ; Zukerman-Schpector & Tiekink (2008) . For related studies on co-crystal formation, see : Broker & Tiekink (2007) ; Broker et al. (2008) ; Ellis et al. (2009) . For structure analysis, see: Spek (2009) . For hydrogenbonding considerations, see: Etter (1990) .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). Symmetry codes: (i) Àx þ 1; Ày þ 2; Àz; (ii) Àx; Ày À 1; Àz þ 2; (iii) x; y þ 1; z; (iv) x; y À 1; z.
Data collection: CrystalClear (Rigaku/MSC, 2005 ); cell refinement: CrystalClear; data reduction: CrystalClear; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: DIAMOND (Brandenburg, 2006) ; software used to prepare material for publication: SHELXL97.
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: HB5194). 
Comment
The co-crystallization of active pharmaceutical ingredients is an active area of contemporary crystal engineering (Shan & Zaworotko, 2008) ; see Zukerman-Schpector & Tiekink (2008) for a discussion of terminology. As a continuation of studies into the phenomenon of co-crystallization (Broker & Tiekink, 2007; Broker et al., 2008; Ellis et al., 2009) , the co-crystallization of DL-pyroglutamic acid with 4,4'-bipyridine was investigated.
The title co-crystal, (I), comprises two molecules of pyroglutamic acid and one of 4,4'-bipyridine, Fig. 1 . The independent molecules of pyroglutamic acid are virtually identical with RMS values for bond distances and angles of 0.006 Å and 0.552°, respectively (Spek, 2009) . The connections between molecules are hydrogen bonds of the type O-H···N, Table 1 , in accord with the strongest donor associating with the strongest acceptor (Etter, 1990) .
The trimeric aggregates associate into a supramolecular chain via eight-membered amide {···HNCO} 2 synthons. The most convenient description of the chain is given in the following terms. Centrosymmetrically related pyroglutamic acid molecules are connected by the {···HNCO} 2 synthons and these are bridged by the 4,4'-bipyridine molecules, Table 1 and The chains are consolidated into the 3-D crystal structure by a large number of C-H···O contacts, the shortest two are listed in Table 1 , as well as π···π interactions involving both pyridyl rings [the closest Cg···Cg i = 3.590 (2) Å where Cg is the ring centroid of N2, C16-C20 for i: 2 -x, -y, 1 -z].
Experimental
Colourless crystals of (I) were isolated from the co-crystallization of 1 molar equivalent of DL-pyroglutamic acid (Fluka, 20 mg) and 4,4'-bipyridine (Aldrich, 12 mg) in methanol/ethanol (1/1, 8 ml); m. pt. 425-427 K.
Refinement
The H-atoms were placed in calculated positions (O-H = 0.84 Å, N-H = 0.88 Å and C-H 0.95-1.00 Å) and were included in the refinement in the riding model approximation with U iso (H) set to 1.2-1.5U eq (carrier atom). supplementary materials sup-8 
